To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

NCT04495322 | Completed Phase 1 DMC

• 1 other identifier: TG-1000-C-01
• Study Type: interventional
• Target: 66
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics profiles of TG-1000 in healthy volunteers, and to evaluate the food effect on pharmacokinetics of single oral dose of TG-1000 in healthy volunteers.

Conditions

Healthy Chinese Volunteers

Outcome Measures

Primary Outcomes (16)

• Number of subjects of treatment-emergent adverse events

  Any significant findings after dosing will be considered as adverse events.

  8 days

• Number of subjects of Significant Abnormal Vital Signs Findings

  The systolic and diastolic blood pressure (mmHg), pulse/heart rate (beats/min), respiratory rate (breaths/min), and body temperature (oC) will be measured.

  8 days

• Number of subjects With Significant Abnormal Physical Examination Findings

  A full general physical examination of the major body systems (General Appearance; Dermatological including skin and nails; Head and Neck; Chest region including Heart and Lung; Abdominal region including Gastrointestinal and Gastroenterology; Back region; Extremities; Psychiatric or Neurological; Lymph nodes; Other) will be performed by investigator.

  8 days.

• Number of subjects With Significant Abnormal 12-lead Electrocardiography (ECG) Findings

  12-lead ECG will be performed after a rest in a supine position. The following ECG parameters will be listed: heart rate, the time between QRS complexes (RR Interval) (ms), the beginning of the P wave to the first deflection of the QRS complex (PR Interval) (ms), first deflection of QRS complex to end of QRS complex at isoelectric line (QRS duration) (ms), first deflection of QRS complex to end of T wave at isoelectric line (QT interval) (ms), Corrected QT interval by Bazett (QTcB) (ms), and Corrected QT interval by - Fridericia (QTcF) (ms).

  8 days

• Number of subjects With Significant Abnormal Holter Electrocardiography (ECG) Findings

  Holter ECG will be monitor continue from 12 hr pre-dose until 24 hr post-dose. The Investigator will determine whether the results of the Holter monitoring are normal or abnormal.

  12 hr pre-dose until 24 hr post-dose

• Number of Participants With Significant Abnormal Laboratory Values

  Chemistry, Hematology, Coagulation, Urinalysis, Human Immunodeficiency Virus (HIV) test, Hepatitis A virus(HAV) test, Hepatitis B virus (HBV) test, Hepatitis C virus (HCV) test, syphilis, serum pregnancy tests and Breath Alcohol Test

  8 days

• Peak Plasma Concentration (Cmax)

  Blood sample will be collected to evaluate PK profile and food effect of TG-1000.

  15 days

• time to Cmax (Tmax)

  Blood sample will be collected to evaluate PK profile of TG-1000.

  15 days

• area under the curve from time zero to the time (AUC0-t)

  Blood sample will be collected to evaluate PK profile and food effect of TG-1000.

  15 days

• area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)

  Blood sample will be collected to evaluate PK profile of TG-1000.

  15 days

• area under the concentration-time curve from time zero to infinity (AUC0-inf)

  Blood sample will be collected to evaluate PK profile and food Effect of TG-1000.

  15 days

• terminal elimination half-life (T1/2, z)

  Blood sample will be collected to evaluate PK profile of TG-1000.

  15 days

• apparent total body clearance (CL/F)

  Blood sample will be collected to evaluate PK profile of TG-1000.

  15 days

• apparent total volume distribution (V/F)

  Blood sample will be collected to evaluate PK profile of TG-1000.

  15 days

• plasma concentration 24 h after dosing (C24)

  Blood sample will be collected to evaluate PK profile of TG-1000.

  15 days

• urinary excretion ratio relative to dose from time zero to the time (Feu0-t)

  Urine sample will be collected to evaluate PK profile of TG-1000.

  15 days

Study Arms (8)

10 mg TG-1000

EXPERIMENTAL

Eligible subjects will receive single oral dose of study drug (2 x 5-mg TG-1000 capsules)on Day 1 under fasted condition.

Drug: TG-1000

20 mg TG-1000 or Placebo

EXPERIMENTAL

Eligible subjects will receive single oral dose of study drug (20 mg TG-1000 capsule or Placebo capsule) on Day 1 under fasted condition.

Drug: TG-1000; Drug: Placebo

40 mg TG-1000 or Placebo

EXPERIMENTAL

Eligible subjects will receive single oral dose of study drug (2 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.

Drug: TG-1000; Drug: Placebo

80 mg TG-1000 or Placebo

EXPERIMENTAL

Eligible subjects will receive single oral dose of study drug (4 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.

Drug: TG-1000; Drug: Placebo

120 mg TG-1000 or Placebo

EXPERIMENTAL

Eligible subjects will receive single oral dose of study drug (6 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.

Drug: TG-1000; Drug: Placebo

160 mg TG-1000 or Placebo

EXPERIMENTAL

Eligible subjects will receive single oral dose of study drug (8 x 20 mg TG-1000 capsules or Placebo capsules) on Day 1 under fasted condition.

Drug: TG-1000; Drug: Placebo

X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed)

EXPERIMENTAL

Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fasted condition. After washout period, subject will receive a single oral dose of TG-1000 under fed condition.

Drug: TG-1000

X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)

EXPERIMENTAL

Based on the preliminary results, one optimal dose (X mg) of TG-1000 will be selected. Subject will receive a single oral dose of TG-1000 under fed condition. After washout period, subject will receive a single oral dose of TG-1000 under fasted condition.

Drug: TG-1000

Interventions

TG-1000 DRUG

Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

10 mg TG-1000; 120 mg TG-1000 or Placebo; 160 mg TG-1000 or Placebo; 20 mg TG-1000 or Placebo; 40 mg TG-1000 or Placebo; 80 mg TG-1000 or Placebo; X mg TG-1000 (fasted)+wash-out+X mg TG-1000 (fed); X mg TG-1000 (fed)+wash-out+X mg TG-1000 (fasted)

Placebo DRUG

Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.

120 mg TG-1000 or Placebo; 160 mg TG-1000 or Placebo; 20 mg TG-1000 or Placebo; 40 mg TG-1000 or Placebo; 80 mg TG-1000 or Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Willing to provide written informed consent.
• Age 18 (or legal adult age) to 45 years.
• Body mass index (BMI) in the range of ≥19.0 to ≤ 24.0 kg/m2 and body weight ≥ 50 kg for male and ≥ 45 kg for female at Screening.
• Subjects have good communication with Investigator and agree to follow the study requirement to complete study.

You may not qualify if:

• Clinically significant abnormality in 12-lead ECG, chest X-ray, abdominal ultrasounds, physical examination, vital signs or laboratory values at Screening or Day-1.
• Positive breath alcohol or urine drug tests at Day-1.
• Positive test results for Immunoglobulin M anti-HAV antibody, HBsAg, anti-HCV antibody, HIV or syphilis at Screening.
• Female subjects with positive pregnancy test results at Screening or Day-1.
• Male subjects are unwilling to use effective contraception and refrain from sperm donation from Screening until 3 months after the study drug administration.
• Current or prior history of any of the following:
• Significant cardiac disease, diabetes, liver, kidney disease, psychiatric diseases or drug abuse or diseases that will affect immunity.
• Difficulty in swallow or gastrointestinal disorder that could interfere with the absorption of the study drug
• Difficulty in blood sampling or venipuncture
• Drug allergy or hypersensitivity
• Blood donation ≥ 400 mL within 3 months before and after study.
• Alcoholics or frequent drinkers prior to Screening.
• Frequent smokers prior to Screening.
• Use of any prohibited medications or surgeries prior to study drug administration:
• a. Received any other investigational agents or devices, liver enzyme inducer or inhibitors, medications including prescriptions, non-prescriptions or herbal remedies, dietary supplements or surgeries.

Sponsors & Collaborators

• TaiGen Biotechnology Co., Ltd.: lead
• R&G Pharma Studies Co.,Ltd.: collaborator

Study Sites (1)

Xiangya Hospital of Central South University

Changsha, Hunan, China

Location

Study Officials

• Pingsheng Xu

  Xiangya Hospital of Central South University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: single-center, randomized, double-blind, placebo-controlled, single-dose

Study Record Dates

• First Submitted: July 22, 2020
• First Posted: July 31, 2020
• Study Start: July 17, 2020
• Primary Completion: November 26, 2020
• Study Completion: December 30, 2020
• Last Updated: January 7, 2021

Record last verified: 2021-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)